RVU Ryvu Therapeutics S.A.

GPW · PL · Healthcare · Biotechnology · ryvu.com
4.196USD16.88 PLN · GPW-0.12%Mkt Cap: 97.02M USDP/E: —

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's l…

Key Statistics

Company
Market Cap97.02M USD
Enterprise Value101.34M USD
Revenue (TTM)20.87M USD
Gross Profit11.80M USD
Net Income (TTM)-25.17M USD
Revenue/Share0.90 USD
Last Price4.196 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees228
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLSELVT00013
Valuation
P/E (Trailing)—
P/E (Forward)6.92
PEG—
EV/EBITDA-6.50
EV/Revenue4.86
P/S4.65
P/B13.76
EPS (TTM)-0.75 USD
EPS (Forward)—
52W Range
3.39118% of range7.931
52W High7.931 USD
52W Low3.391 USD
Profitability
Gross Margin76.22%
Oper. Margin-85.01%
EBITDA Margin-74.71%
Profit Margin-162.61%
ROE-188.04%
ROA-45.10%
ROIC-443.22%
ROCE-59.69%
Growth
Revenue Growth-20.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.37M USD
CapEx (TTM)1.86M USD
FCF Margin14.20%
FCF Yield3.05%
Net Debt4.31M USD
Net Debt/EBITDA-0.28
Net Debt/FCF1.46
Balance Sheet
Debt/Equity1.33
Current Ratio2.14
Quick Ratio1.95
Book Value/Sh0.31 USD
Cash/Share0.80 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.433 USD
Upside (mean)+77.1%
Target Range4.226 USD – 11.44 USD
4.226+77.1% to mean11.44
# Analysts5
Ownership
Shares Out.23.12M
Float15.99M
Insiders35.02%
Institutions24.28%
Technical
SMA 504.177 (+0.5%)
SMA 2004.746 (-11.6%)
Beta0.36
S&P 52W Chg12.00%
Avg Vol (30d)31.55K
Avg Vol (10d)15.39K
Technical Indicators
RSI (14)50.5
MACD0.0925
MACD Signal0.1272
MACD Hist.-0.0346
BB Upper4.665 USD
BB Middle4.197 USD
BB Lower3.730 USD
BB Width22.28%
ATR (14)0.2107 USD
Vol Ratio (20d)0.24x

About Ryvu Therapeutics (WSE: RVU)

›

Ryvu Therapeutics (WSE: RVU) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 228 employees.

The shares were at 16.88 PLN on 19 November 2026, down 45.4% over 52 weeks. Its 52-week range is 13.64 PLN to 31.90 PLN: the price is 47.1% below the high and 23.8% above the low.

Its market capitalisation is 390.27M PLN.

Ryvu Therapeutics reports return on equity of -188.0%, an operating margin of -85.0% and revenue down 20.8% year over year.

Its debt exceeds its cash by 17.35M PLN, a debt-to-equity ratio of 1.33. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 29.90 PLN is 77.1% above the current price.